LONDON – Shield Therapeutics Ltd. is to raise up to £110 million (US$168 million) in an IPO on the London Stock Exchange, providing funding to push its anemia and hyperphosphatemia treatments through FDA and EMA approvals and build its own sales infrastructure to market the drugs.